RADLogics

Executive Summary

RADLogics is an Israeli AI-driven medical imaging company that retrospectively analyzes archived DICOM scans to detect previously undiagnosed cancers, with an initial focus on lung cancer from chest CTs. Its patented platform integrates seamlessly with hospital PACS, enabling providers to uncover actionable findings without workflow disruption. Founded in 2020, the company operates in the platform stage and has a team of 50–200 employees. By repurposing existing imaging data, RADLogics aims to improve patient outcomes and generate new revenue streams for healthcare providers, addressing a significant gap in early cancer detection. The company operates in the growing AI diagnostics market and has potential for substantial impact, but lacks disclosed funding or revenue data, making its financial trajectory uncertain.

Upcoming Catalysts (preview)

• Q4 2026FDA Clearance for Lung Cancer Detection Algorithm60% success
• H2 2026Partnership with Major US Hospital System50% success
• H1 2027Series A Funding Round70% success